Innoviva, Inc.
INVAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Innoviva, Inc. focuses on Biotechnology services and products. Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Valued at $1.60B, INVA is a small-cap name in its sector. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
Market Cap
$1.60B
Beta
0.34
P/E (TTM)
3.55
P/E (Fwd)
9.82
EPS (TTM)
$6.12
EPS (Fwd)
$2.21
ROE
50.7%
ROA
6.7%
Cash
$611.9M
Total Debt
$331.4M
Free CF
$105.2M
52W Change
10.9%
Annual Financials
Cash vs Debt
Innoviva, Inc. holds $611.9M in cash against $331.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $105.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 50.7%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 6.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $331.3M (2022) to $411.3M (2025), reflecting a 24% increase over the period.
With a beta below 0.7, Innoviva, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Innoviva, Inc. and its sector.